Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
3.4.2024 13:55:00 EEST | Business Wire | Press release
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.
Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”
The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.
“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.
About Conformation-X Therapeutics
Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.
Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
About Pledge Therapeutics
Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.
Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403623298/en/
Contact information
Media
Ali H. Munawar, Ph.D.
amunawar@conformationx.com
1-339-502-8643
Maria Martin
mmartin@pledge-tx.com
1-339-502-8630
Krishna Kandala
kkandala@pledge-tx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Civil Air Patrol Orders 21 New Cessna Aircraft to Strengthen Lifesaving and Community Missions21.10.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an order from Civil Air Patrol (CAP) for 21 additional Cessna piston aircraft that will support CAP's emergency response, training and community missions across the U.S. Deliveries are expected to be completed in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021955281/en/ Maj. Gen. Regena Aye and Brig. Gen. R. Jason Bailey of the Civil Air Patrol tour Cessna piston assembly at Textron Aviation’s facility in Independence, Kansas The order includes seven Cessna Skyhawk 172 aircraft, 11 Cessna Skylane 182 aircraft, two Cessna Turbo Skylane T182T aircraft and one Cessna Turbo Stationair HD 206 aircraft. CAP is the world's largest operator of Cessna aircraft. “These Cessna aircraft help ensure our members are ready when communities need us, whether searching for someone who is missing, responding after a disaster, or introducing young people to a
i2c Marks a Year of Momentum Driving Financial Institutions and Fintechs in the Race to Modernize21.10.2026 16:00:00 EEST | Press release
i2c Inc., a global financial technology innovator, today recapped key milestones from the past year as financial institutions and fintechs raced to modernize their banking and payments technology. Behind that race is mounting pressure. New American Banker research in partnership with i2c found that 88% of financial institutions have accelerated their modernization timelines due to competition from digital-first banks, fintechs, and non-bank providers, with executives most often citing legacy processing architecture as the greatest barrier. Too many remain stuck choosing between legacy platforms with proven scale and modern platforms with agility. For more than 26 years, i2c has helped clients skip that trade-off entirely. i2c’s next-gen PowerOne unified banking and payments platform gives clients one global foundation to outperform competitors running on fragmented legacy stacks, composable building-block solutions to outpace a shifting market, and trusted industry ingenuity to outmane
Klarna Launches Consumer FX: Shop From Klarna Merchants Worldwide, Regardless of Currency21.10.2026 15:47:00 EEST | Press release
Klarna Group Plc (NYSE: KLAR), the everyday finance network, today launched Consumer FX, which allows shoppers to buy from any participating Klarna merchant in the world and pay in their own currency, with no exchange fee. The price and rate are shown upfront and stay visible in the Klarna app after purchase, so there are no surprises on the statement. The new launch means any Klarna connected merchant can sell to Klarna’s 120 million consumers in 26 countries with no new integration, and no need for a local entity of foreign bank account. Klarna also handles FX disclosure, consent and compliance. Early results show merchants gain a 5% lift in conversion and 6% in sales due to the expanded reach. The launch comes as cross-border payments are growing globally. DHL reports that 70% of 2026 shoppers buy internationally, up 10% from 2025, and 45% buy across borders more than once a month.1 “Increasingly, shoppers aren’t thinking in borders,” says David Sykes, Chief Commercial Officer, Klar
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors21.10.2026 15:35:00 EEST | Press release
Merck, a leading science and technology company, today announced a collaboration with NVIDIA Corporation (Santa Clara, California, USA), Microsoft Corporation (Redmond, Washington, USA) and Dawn Health A/S (Copenhagen, Denmark) to build an innovative model for Patient Support Programs (PSPs). The four-way collaboration brings together pharmaceutical and clinical expertise, enterprise technology, AI services and digital health product design, with the shared goal of making specialist-level support more individualized, responsive and continuously available to patients, no matter how complex their treatment journey is. “Across their treatment journeys, patients with rare tumors often describe challenges that extend well beyond clinical care, like navigating multiple specialists, complex regimens and repeatedly reconstructing their treatment story for each new stakeholder. Our integrated support ecosystem starts with the need. The goal is to truly transform how healthcare is experienced, n
Corpay Cross-Border Named the Official FX Partner of Newcastle United21.10.2026 15:30:00 EEST | Press release
Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into a multi-year agreement with Newcastle United to become their Official Foreign Exchange (FX) Partner. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Newcastle United’s day-to-day business operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “We’re thrilled to be named the Official FX Partner of Newcastle United, one of the Premier League’s most iconic and ambitious clubs,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership further strengthens Corpay’s position as the trusted corporate payments and currency risk management provider of choice across the Premier League. We look forward to supporting the club throughout what promises to be an exciting seaso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom